Gemini Therapeutics (GMTX) Key Ratios
$23.93
$2.71
(12.77%)
As on 17-Feb-2023 09:30EDT
Market cap
$58 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | 48.34 | 79.74 | 20.08 | -213.25 | -- |
| Net Profit | 53.78 | 82.34 | 20.85 | -- | -- |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-21 | Dec-20 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -8,666.87 | -- | -- |
| Return on equity
| -30.03 | -- | -40.17 | -59.37 | -0.69 |
| Return on Capital
| -29.73 | -- | -- | -58.07 | -1.39 |
| Return on Assets
| -27.71 | -- | -31.50 | -54.75 | -0.67 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.04 | -- |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
--
|
-58.07
|
-1.39
|
--
|
--
|
||||||
|
Peer Median
|
ROE
-40.17
Lower than Peers by 13.86
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
-40.17
|
-59.37
|
-0.69
|
--
|
--
|
||||||
|
Peer Median
|
-26.31
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
ROA
-31.50
Lower than Peers by 18.54
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
-31.50
|
-54.75
|
-0.67
|
--
|
--
|
||||||
|
Peer Median
|
-12.96
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Net Margin
-8,666.87
Lower than Peers by 8,595.81
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
-8,666.87
|
--
|
--
|
--
|
--
|
||||||
|
Peer Median
|
-71.06
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
EBIT Growth
20.08
Higher than Peers by 4.88
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
20.08
|
-8,479.87
|
98.03
|
-104.18
|
--
|
||||||
|
Peer Median
|
15.20
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Net Profit Growth
20.85
Higher than Peers by 12.99
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
20.85
|
-8,745.47
|
--
|
--
|
--
|
||||||
|
Peer Median
|
7.86
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
--
|
0.04
|
--
|
--
|
--
|
||||||
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
--
|
0.04
|
--
|
--
|
--
|
||||||
|
Peer Median
|
Current Ratio
71.49
Higher than Peers by 68.01
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
71.49
|
9.44
|
2.24
|
0.58
|
4.74
|
||||||
|
Peer Median
|
3.48
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Quick Ratio
71.49
Higher than Peers by 68.20
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
71.49
|
--
|
--
|
--
|
--
|
||||||
|
Peer Median
|
3.29
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Interest Coverage
-179.92
Lower than Peers by 178.41
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
-179.92
|
-32.30
|
-0.12
|
--
|
--
|
||||||
|
Peer Median
|
-1.51
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
--
|
--
|
--
|
--
|
--
|
||||||
|
Peer Median
|
0.23
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Valuation
Price / Book Value
0.68
Lower than Peers by 4.28
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
0.68
|
--
|
--
|
--
|
--
|
||||||
|
Peer Median
|
4.96
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
--
|
--
|
--
|
--
|
--
|
||||||
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
EV/EBITDA
0.79
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
0.79
|
1.89
|
2.47
|
--
|
--
|
||||||
|
Peer Median
|
Market Cap
58
Lower than Peers by 25
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemini Therapeutics (GMTX)
|
58
|
--
|
--
|
--
|
--
|
||||||
|
Peer Median
|
83
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
